Q18 – What are the key considerations when treating patients with XLH?

Q20 – Some patients may need to switch off from Burosumab back to conventional therapy. How would you manage such patients, and when should patients restart conventional therapy?

Q16 – What is your experience with regards to growth rates in patients taking Burosumab? Has there been cases when growth rates became slower after taking Burosumab?

Key Clinical Questions about the diagnosis / treatment for XLH and Burosumab (Prof Craig F. Munns)

(Full Video)

You are using an insecure Internet browser
We have noticed that you are using Internet Explorer which is an outdated and insecure Internet browser. Please use one of the browsers below for a safe and optimal experience on our website. Thank you.
Edge	Firefox	Chrome

You are using an insecure Internet browser

This website is intended for healthcare professionals only

Q18 – What are the key considerations when treating patients with XLH?

Q18 – What are the key considerations when treating patients with XLH?

Q19 – What considerations should clinicians take into account with regards to Covid-19 vaccinations in patients on Burosumab?

Q20 – Some patients may need to switch off from Burosumab back to conventional therapy. How would you manage such patients, and when should patients restart conventional therapy?

Clinical Questions on XLH and Burosumab (Prof Thomas O. Carpenter)

Q1 – Why is it important to restore and maintain life-long phosphate homeostasis in patients with X-Linked Hypophosphatemia (XLH)?

Q2 – What specialists or multidisciplinary care team should be involved in the care of XLH patients? And how?

Q4 – How important is Burosumab in the treatment of XLH?

Q5 – For which XLH patients should Burosumab be considered?

Q6 – What is your experience on the efficacy of Burosumab in children with XLH?

Q7 – What is your experience on dental abscess in patients receiving Burosumab? How do you manage dental abscess in patients on Burosumab?

Q9 – How do you manage side effects such as fever and headaches in patients receiving Burosumab?

Q14 – How do you manage low serum Vitamin D levels in patients on Burosumab?

Q16 – What is your experience with regards to growth rates in patients taking Burosumab? Has there been cases when growth rates became slower after taking Burosumab?

Q17 – What is your experience in transition of care from pediatrics to adults in XLH setting? What does good look like in transition of care?

More Videos

Key Clinical Questions about the diagnosis / treatment for XLH and Burosumab (Prof Craig F. Munns)

An update on X-Linked Hypophosphatemia in Children and Adolescents (Prof Zulf Mughal)

This website is for healthcare professionals only, please login below or

Welcome to Crysvita.Asia website!

You are using an insecure Internet browser

This website is intended for healthcare professionals only

Q18 – What are the key considerations when treating patients with XLH?

Related videos

Q18 – What are the key considerations when treating patients with XLH?

Q19 – What considerations should clinicians take into account with regards to Covid-19 vaccinations in patients on Burosumab?

Q20 – Some patients may need to switch off from Burosumab back to conventional therapy. How would you manage such patients, and when should patients restart conventional therapy?

Clinical Questions on XLH and Burosumab (Prof Thomas O. Carpenter)

Q1 – Why is it important to restore and maintain life-long phosphate homeostasis in patients with X-Linked Hypophosphatemia (XLH)?

Q2 – What specialists or multidisciplinary care team should be involved in the care of XLH patients? And how?

Q4 – How important is Burosumab in the treatment of XLH?

Q5 – For which XLH patients should Burosumab be considered?

Q6 – What is your experience on the efficacy of Burosumab in children with XLH?

Q7 – What is your experience on dental abscess in patients receiving Burosumab? How do you manage dental abscess in patients on Burosumab?

Q9 – How do you manage side effects such as fever and headaches in patients receiving Burosumab?

Q14 – How do you manage low serum Vitamin D levels in patients on Burosumab?

Q16 – What is your experience with regards to growth rates in patients taking Burosumab? Has there been cases when growth rates became slower after taking Burosumab?

Q17 – What is your experience in transition of care from pediatrics to adults in XLH setting? What does good look like in transition of care?

More Videos

Key Clinical Questions about the diagnosis / treatment for XLH and Burosumab (Prof Craig F. Munns)

An update on X-Linked Hypophosphatemia in Children and Adolescents (Prof Zulf Mughal)

This website is for healthcare professionals only, please login below or

Welcome to Crysvita.Asia website!